Strike three: Allergan slides on potential Restasis generics

Allergan came out swinging at the beginning of 2013, but the Irvine, California-based company faced its third strike of the year when the US FDA issued guidance for generic drug makers developing reduced-priced competition for the dry eye drug Restasis (cyclosporine).